Considering that tumor cells may downregulate MHC class I molecules during tumor progression (32, 42), the absence of HLA-A2 confirmation at the treatment stage represents a potential limitation, as it may affect the efficiency of NY-ESO-1 TCR-T cell recognition. This evidence concerns the gene CTAG1B and neoplasm.